Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.

@article{Elhai2013OutcomesOP,
  title={Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.},
  author={Muriel Elhai and Marine Meunier and Marco Matucci-Cerinic and Britta Maurer and Gabriela Riemekasten and Tifenn Leturcq and Raffaele A Pellerito and Carlos Alberto von M{\"u}hlen and Alessandra Vacca and Paolo Air{\'o} and Francesca Bartoli and Ginevra Fiori and Maria Bokarewa and Valeria Riccieri and Mike Becker and J{\'e}r{\^o}me Avouac and Ulf Mueller-Ladner and Oliver Distler and Yannick Allanore},
  journal={Annals of the rheumatic diseases},
  year={2013},
  volume={72 7},
  pages={1217-20}
}
OBJECTIVE To evaluate the safety and effectiveness of tocilizumab and abatacept in systemic sclerosis (SSc)-polyarthritis or SSc-myopathy. METHODS 20 patients with SSc with refractory polyarthritis and seven with refractory myopathy from the EUSTAR (EULAR Scleroderma Trials and Research) network were included: 15 patients received tocilizumab and 12 patients abatacept. All patients with SSc-myopathy received abatacept. Clinical and biological assessments were made at the start of treatment… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
30 Citations
20 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…